Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bisegliptin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 20/20 | 0.64 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.54 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.54 |
| ▸ | PREP | P48147 | 1/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bisegliptin SCHEMBL196882 | 1.00 | DPP4 (0.64) | DPP4DPP8DPP9PREPDPP7 | |
| Bisegliptin SCHEMBL2047576 | 0.99 | DPP4 (0.62) | DPP4DPP8DPP9PREPDPP7 | |
| Bisegliptin SCHEMBL2046787 | 0.99 | DPP4 (0.62) | DPP4DPP8DPP9PREPDPP7 | |
| Bisegliptin SCHEMBL2046833 | 0.97 | DPP4 (0.60) | DPP4DPP8DPP9PREPDPP7 | |
| Bisegliptin SCHEMBL2049664 | 0.97 | DPP4 (0.60) | DPP4DPP8DPP9PREPDPP7 | |
| Bisegliptin SCHEMBL2044893 | 0.97 | DPP4 (0.60) | DPP4DPP8DPP9PREPDPP7 | |
| Bisegliptin SCHEMBL2051793 | 0.96 | DPP4 (0.59) | DPP4DPP8DPP9PREPDPP7 | |
| Bisegliptin SCHEMBL2043885 | 0.96 | DPP4 (0.59) | DPP4DPP8DPP9PREPDPP7 | |
| Bisegliptin SCHEMBL2048333 | 0.96 | DPP4 (0.59) | DPP4DPP8DPP9PREPDPP7 | |
| Bisegliptin SCHEMBL2049221 | 0.95 | DPP4 (0.58) | DPP4DPP8DPP9PREPDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014074668-A1 | MODULATORS OF GPR119 AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2014-05-15 | — | — | WO | claimed |
| WO-2011005929-A1 | PIPERIDINE DERIVATIVE AND ITS USE FOR THE TREATMENT OF DIABETS AND OBESITY | ARENA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | claimed |
| US-20210340133-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2021-11-04 | — | — | US | disclosed |
| US-20160089373-A1 | CARDIO- AND RENOPROTECTIVE ANTIDIABETIC THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2016-03-31 | — | — | US | disclosed |
| US-20160058769-A1 | TREATMENT FOR DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH AN ORAL OR NON-ORAL ANTIDIABETIC DRUG | BOEHRINGER INGELHEIM INT (DE) | 2016-03-03 | — | — | US | disclosed |
| EP-2990037-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | Boehringer Ingelheim International GmbH (DE) | 2016-03-02 | — | — | EP | disclosed |
| EP-2854824-A1 | USE OF KERATINOCYTES AS A BIOLOGICALLY ACTIVE SUBSTANCE IN THE TREATMENT OF WOUNDS, SUCH AS DIABETIC WOUNDS, OPTIONALLY IN COMBINATION WITH A DPP-4 INHIBITOR | Boehringer Ingelheim International GmbH (DE) | 2015-04-08 | — | — | EP | disclosed |
| WO-2014074668-A1 | MODULATORS OF GPR119 AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2014-05-15 | — | — | WO | disclosed |
| WO-2013174769-A1 | USE OF KERATINOCYTES AS A BIOLOGICALLY ACTIVE SUBSTANCE IN THE TREATMENT OF WOUNDS, SUCH AS DIABETIC WOUNDS, OPTIONALLY IN COMBINATION WITH A DPP-4 INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-28 | — | — | WO | disclosed |
| EP-2619198-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-2611781-A1 | FAST-DISSOLVE DOSAGE FORMS OF 5-HT2C AGONISTS | Arena Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-2611427-A2 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT& xA; | Arena Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012145361-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012145604-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012145603-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012040279-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012030951-A1 | FAST-DISSOLVE DOSAGE FORMS OF 5-HT2C AGONISTS | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030927-A2 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030938-A1 | SALTS OF LORCASERIN WITH OPTICALLY ACTIVE ACIDS | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2011005929-A1 | PIPERIDINE DERIVATIVE AND ITS USE FOR THE TREATMENT OF DIABETS AND OBESITY | ARENA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160058769-A1 | TREATMENT FOR DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH AN ORAL OR NON-ORAL ANTIDIABETIC DRUG | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 5/4885DPP9 4/4885 |
| US-20210340133-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | GPR119, GLP1R, SLC5A2 | DPP4 4/4885DPP8 10/4885DPP9 7/4885 |
| US-20160089373-A1 | CARDIO- AND RENOPROTECTIVE ANTIDIABETIC THERAPY | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 4/4885DPP9 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.